title: The expression and significance of the enhancer of zeste homolog 2 in             lung adenocarcinoma.
abstract: Lung adenocarcinoma, with increased incidence in the world, exhibits poor             prognosis and is usually resistant to conventional chemotherapy due to drug resistance.             The enhancer of zeste homologue 2 (EZH2), a histone methyltransferase, plays a             key role in tumorigenesis and cancer development through chromatin remodeling             in various types of cancer. However, its potential role in lung adenocarcinoma             has not been well defined. In this study, the expression of EZH2 was examined             in lung adenocarcinoma tissues and cell lines. Most interestingly, EZH2 overexpression             was detected in tumor tissue and significantly correlated with histological differentiation,             pathological tumor-node-metastasis stage and smoking history, but not with gender             or age. Furthermore, EZH2 overexpression was also detected in cisplatin-resistant             cancer cells rather than cisplatin-sensitive cells. Short hairpin RNA targeted             against EZH2 inhibited cell proliferation and migration, and led to G(2)/M cell             cycle arrest and apoptosis in both cisplatin-resistant and cisplatin-sensitive             cell lines. Moreover, EZH2 knockdown enhanced cisplatin sensitivity of cisplatin-resistant             cells and reduced the expression levels of multidrug resistance-related protein             1. Our study suggests that EZH2 contributes to the progression of lung adenocarcinoma,             and the deletion of EZH2 inhibits cancer and resensitizes cells to cisplatin in             lung adenocarcinoma.
authors.affiliation: Department of Traditional Chinese Medicine, Qilu Hospital, Shandong University, Jinan 250012, PR China.
authors.forename: Yijing
authors.initials: Y
authors.lastname: Lv
authors.forename: Cunzhong
authors.initials: C
authors.lastname: Yuan
authors.forename: Xiaoyan
authors.initials: X
authors.lastname: Xiao
authors.forename: Xuping
authors.initials: X
authors.lastname: Wang
authors.forename: Xuming
authors.initials: X
authors.lastname: Ji
authors.forename: Huayun
authors.initials: H
authors.lastname: Yu
authors.forename: Zhichun
authors.initials: Z
authors.lastname: Wu
authors.forename: Jidong
authors.initials: J
authors.lastname: Zhang
mesh_terms: D000230:Adenocarcinoma / Q000378:metabolism*; D000077192:Adenocarcinoma of Lung; D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000494:pharmacology; D017209:Apoptosis; D059447:Cell Cycle Checkpoints; D045744:Cell Line, Tumor; D002465:Cell Movement; D002467:Cell Nucleus / Q000378:metabolism; D049109:Cell Proliferation; D002945:Cisplatin / Q000494:pharmacology; D004268:DNA-Binding Proteins / Q000235:genetics / Q000378:metabolism*; D019008:Drug Resistance, Neoplasm; D000071221:Enhancer of Zeste Homolog 2 Protein; D005260:Female; D015870:Gene Expression; D055785:Gene Knockdown Techniques; D006801:Humans; D008175:Lung Neoplasms / Q000378:metabolism*; D008297:Male; D008875:Middle Aged; D027425:ATP-Binding Cassette, Sub-Family C Proteins / Q000235:genetics / Q000378:metabolism; D063151:Polycomb Repressive Complex 2; D034622:RNA Interference; D014157:Transcription Factors / Q000235:genetics / Q000378:metabolism*
chemical_list: D000970:Antineoplastic Agents; D002945:Cisplatin; D004268:DNA-Binding Proteins; D000071221:Enhancer of Zeste Homolog 2 Protein; D027425:ATP-Binding Cassette, Sub-Family C Proteins; D063151:Polycomb Repressive Complex 2; D014157:Transcription Factors; C498409:EZH2 protein, human; C421109:multidrug resistance-associated protein 1